Cargando…
In vivo acquired sorafenib-resistant patient-derived tumor model displays alternative angiogenic pathways, multi-drug resistance and chromosome instability
Acquired resistance to targeted therapies is an important clinical challenge. Research focusing on acquired resistance is hindered by the lack of relevant model systems. In the present study, the generation and characterization of an in vivo acquired sorafenib-resistant hepatocellular carcinoma (HCC...
Autores principales: | Hu, Gang, Zhang, Yixin, Ouyang, Kedong, Xie, Fubo, Fang, Houshun, Yang, Xueyang, Liu, Kunyan, Wang, Zongyu, Tang, Xuzhen, Liu, Jibin, Yang, Lei, Jiang, Zhenzhou, Tao, Weikang, Zhou, He, Zhang, Luyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096179/ https://www.ncbi.nlm.nih.gov/pubmed/30127946 http://dx.doi.org/10.3892/ol.2018.9078 |
Ejemplares similares
-
Establishment and Characterization of 7 Novel Hepatocellular Carcinoma Cell Lines from Patient-Derived Tumor Xenografts
por: Xin, Hong, et al.
Publicado: (2014) -
Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
por: Yuen, J S P, et al.
Publicado: (2011) -
Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020) -
Microvesicles: the functional mediators in sorafenib resistance
por: He, Cong, et al.
Publicado: (2022) -
Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)